Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 474-477

  Novarino, A ^a   Chiappino, I ^a   Bertelli, G F ^b   Heouaine, A ^c   Ritorto, G ^a   Addeo, A ^a   Bellone, G ^d   Merlano, M ^c   Bertetto, O ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b SINGLETON HOSPITAL   (United Kingdom)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

5 fluorouracil; Chemotherapy; Cisplatin; Gemcitabine; Pancreatic cancer; Phase II study

Indexed keywords

ANALGESIC AGENT; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; GEMCITABINE; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLEEN INFARCTION; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOCYTOSIS; VEIN THROMBOSIS; VOMITING;

EID: 1842503065     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh106     Document Type: Article

References (33)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-885.
3. Glimelius B, Hoffmann K, Sjöden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
4. Cullinan S, Moertel CG, Wieand HS et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinsons regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 1990; 65: 2207-2212.
5. Burris HA III, More JA, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer. A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
6. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996; 7: 347-353.
7. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Groups Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
8. Hidalgo M, Castellano D, Paz-Ares L H et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17: 585-592.
9. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
10. Cascinu S, Labianca R, Catalano V et al. Weekly gemcitabine and cisplatin chemotherapy: A well tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2003; 14: 205-208.
11. Cascinu S, Gasparini G, Catalano V et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999; 10: 1377-1379.
12. Ryan DP, Kulke MH, Fuchs CS et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94: 97-103.
13. Rocha Lima C, Savarese D, Bruckner H et al. Multicenter phase II trial of first line irinotecan and gemcitabine (Irinogem) in patients with locally advanced or metastatic pancreatic cancer (PC). Proc Am Soc Clin Oncol 2000; 19: 263a.
14. Stathopulos G, Rigatos G, Dimopulos M et al. Front line treatment of pancreatic carcinoma with gemcitabine (GMB) in combination with irinotecan (CPT-11): Preliminary results of a multicenter phase II study. Proc Am Soc Clin Oncol 2000; 19: 319a.
15. Scheithauer W, Kornek GV, Raderer M et al. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 1999; 80: 1797-1802.
16. Bergman AM, Ruiz van Haperen VW, Veerman G et al. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Purine Pyrimidine Metab Man 1995; 7: 139-143.
17. Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT 29 colon cancer cells. Clin Cancer Res 1998; 4: 2811-2818.
18. Schulz L, Schalhorn A, Wilmanns W et al. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells. Proc Am Soc Clin Oncol 1998; 17: 251a.
19. Wils JA, Kok T, Wagener DJ et al. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993; 29A: 203-204.
20. Bertheault-Cvitkovic F, Levi F, Soussan S et al. Circadian rhythm modulated chemotherapy with high dose 5-fluorouracil: A pilot study in patients with pancreatic adenocarcinoma. Eur J Cancer 1993; 29A: 1851-1854.
21. Simon R. Optimal stage design for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
22. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemicitabine (2′-2′-difluorodeoxycitidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
23. Carmichael J, Fink U, Russel RCG et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-105.
24. Ducreux M, Rougier P, Pignon JP et al. On behalf of the Groupe Digestif of the Fédération Nationale des Centres de Lutte Contre le Cancer Digestif (GDFNCLCC). A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002; 13: 1185-1191.
25. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002: 95 (Suppl 4): 912-922.
26. Heinemann V. Gemcitabine-based combination treatment of pancreatic cancer. Sem Oncol 2002; 29 (Suppl 4): 25-35.
27. Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17: 585-592.
28. Louvet C, Andre T, Hammel P et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001; 12: 675-679.
29. Rauch DP, Maurer CA, Aebi Set al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology 2001; 60: 43-48.
30. Heinemann V, Wilke H, Mergenthaler HW et al. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
31. Heinemann V, Quietzsch D, Schoenekaes H et al. Randomized phase III study in advanced and metastatic and pancreatic cancer: Single agent gemcitabine versus gemcitabine plus cisplatin. Eur J Cancer 2001; 37 (Suppl 6): 1151.
32. Shepherd FA, Abratt R, Crino L et al. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer 2000; 30: 117-125.
33. Kroep JR, Peters GJ, van Moersel CJ et al. Gemcitabine-cisplatin: A schedule finding study. Ann Oncol 1999; 10: 1503-1510.